| Oct 29 |
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
|
| Oct 28 |
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
|
| Oct 23 |
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
|
| Oct 22 |
Coya Therapeutics looks to raise $10M in private placement
|
| Oct 22 |
Coya Therapeutics Announces $10.0 Million Private Placement
|
| Oct 13 |
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
|
| Oct 8 |
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
|
| Sep 24 |
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
|
| Sep 16 |
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
|
| Sep 3 |
Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
|
